Fortress Biotech, Inc.
NASDAQ:FBIOBiotechnology
-$0.06 today
- Market cap
- $63.03M
- Beta
- 1.23
- P/E (TTM)
- 0.7
- EPS (TTM)
- $4.05
Volume 0.41M
Average 0.43M
FBIO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Fortress Biotech, Inc.NASDAQ: FBIO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q1 FY2026 stock-based compensation was $0, compared with $6.29M a year earlier. Trailing-twelve-month stock-based compensation was $22.45M. Over 3 fiscal years it compounded at +7.7% a year.
Context
- Stock-based compensation amounted to 45.4% of revenue in FY2025, down 11.1 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $5.61M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 28.74M USD
- Year-over-year change
- -11.9%
- 4-year CAGR
- +10.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.74M | -11.9% |
| FY2024 | 2024-12-31 | 32.62M | +91.5% |
| FY2023 | 2023-12-31 | 17.03M | -25.9% |
| FY2022 | 2022-12-31 | 22.99M | +18.0% |
| FY2021 | 2021-12-31 | 19.49M | — |
Stock-Based Compensation vs competitors
How FBIO compares with its peers on the latest reported figures
- FBIO's LTM Mar 2026 stock-based compensation of $22.45M is the largest of the 10 companies compared; the peer median is $7.27M.
- Its year-over-year change of -34.1% is the 7th highest of 9, against a peer median of -25.4%.
- Stock-based compensation amounts to 33.9% of revenue for FBIO, versus a peer median of 148.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.45M | -34.1% | +7.7% | 33.9% | |
| LTM Mar 2026 | $13.93M | -47.2% | -30.3% | — | |
| LTM Mar 2026 | $11.29M | +44.4% | +3.8% | — | |
| LTM Mar 2026 | $10.76M | -2.0% | +37.0% | 117.7% | |
| LTM Mar 2026 | $7.34M | -25.5% | -15.1% | 2.9% | |
| LTM Jun 2024 | $7.27M | — | -29.1% | 891.4% | |
| LTM Mar 2026 | $5.81M | -25.3% | -16.6% | — | |
| LTM Apr 2026 | $3.23M | +3574.0% | -47.8% | 179.0% | |
| LTM Mar 2026 | $1.79M | -31.8% | +5.7% | — | |
| LTM Mar 2026 | $465K | -90.1% | -10.6% | — | |
| Peer median (excluding FBIO) | $7.27M | -25.4% | -15.1% | 148.4% | |
Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (164.83M) | (213.91M) | (154.15M) | (120.86M) | (32.92M) |
| Depreciation & Amortization | 6.79M | 9.35M | 6M | 4.46M | 4.66M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 19.49M | 22.99M | 17.03M | 32.62M | 28.74M |
| Change in Working Capital | 36.37M | (715K) | (12.52M) | (8.13M) | (25.1M) |
| Accounts Receivables | 834K | (4.84M) | 12.52M | 4.47M | (19.33M) |
| Inventory | (8.46M) | 1.74M | 3.95M | (4.23M) | 4.81M |
| Accounts Payables | 43.31M | 8.35M | (24.38M) | (6.39M) | (7.97M) |
| Other Working Capital | 690K | (5.97M) | (4.61M) | (1.98M) | (2.6M) |
| Other Non-Cash Items | (14.36M) | 2.89M | 15.42M | 11.71M | (41.17M) |
| Operating Cash Flow | (116.54M) | (179.4M) | (128.23M) | (80.19M) | (65.78M) |
| Capital Expenditures | (16.35M) | (3.06M) | (8.1M) | (15M) | 0 |
| Acquisitions (Net) | 56.86M | (20M) | 0 | 0 | 8.96M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (11.78M) | (213K) | (2.04M) | 0 | 1.17M |
| Investing Cash Flow | 40.51M | (22.93M) | (2.1M) | (15M) | 10.12M |
| Debt Repayment | (9.64M) | 49.25M | (38.79M) | (7.33M) | (5.64M) |
| Common Stock Issued | 155.26M | 40.26M | 80.38M | 82.84M | 84.63M |
| Common Stock Repurchased | 0 | (1.11M) | 0 | 0 | (265K) |
| Dividends Paid | (8.78M) | (8.78M) | (8.77M) | (4.71M) | (664K) |
| Other Financing Activities | (4.8M) | (6.74M) | (529K) | (163K) | (360K) |
| Financing Cash Flow | 148.99M | 75.32M | 32.74M | 70.64M | 77.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 72.97M | (127.01M) | (97.59M) | (24.55M) | 21.79M |
| Free Cash Flow | (132.89M) | (182.46M) | (136.32M) | (95.19M) | (65.78M) |
Fortress Biotech, Inc.
NASDAQ:FBIO
Intrinsic Alpha fair value
Locked
Current Price
$1.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.